Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 11, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

[Small-cell lung cancer].

J L Pérez-Gracia1, J M López-Picazo, S Martín-Algarra

  • 1Departamento de Oncología, Cínica Universítaria, Facultad de Medicina, Universidad de Navarra, Pamplona. jlgracia@unav.es

Revista De Medicina De La Universidad De Navarra
|September 25, 2007
PubMed
Summary

Small cell lung cancer is aggressive but highly responsive to treatments like chemotherapy and radiotherapy. This sensitivity makes it a key model for developing novel therapies, including targeted and immunotherapeutic approaches.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).

ESMO open·2026
Same author

ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same author

Comparison of staging using [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT and histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection.

Revista espanola de medicina nuclear e imagen molecular·2024
Same author

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.

ESMO open·2024

Area of Science:

  • Oncology
  • Medical Research

Context:

  • Small cell lung cancer (SCLC) is characterized by rapid progression and early metastasis, posing significant clinical challenges.
  • Despite its aggressiveness, SCLC exhibits remarkable sensitivity to conventional treatments such as chemotherapy and radiotherapy.

Purpose:

  • To highlight the unique dual nature of SCLC as both aggressive and treatment-sensitive.
  • To underscore its role as a critical model for evaluating innovative therapeutic strategies in oncology.

Summary:

  • SCLC's rapid growth and metastatic potential make it highly aggressive.
  • Its pronounced sensitivity to chemotherapy and radiotherapy offers opportunities for long-term survival in limited-stage disease.
  • Established treatment modalities include concomitant chemoradiotherapy, alternant chemotherapy, high-dose chemotherapy, and prophylactic cranial irradiation.

Related Experiment Videos

Last Updated: Jul 11, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Impact:

  • SCLC serves as a vital platform for advancing new treatments, including targeted therapies and immunotherapies.
  • Research into SCLC contributes to broader advancements in solid tumor treatment strategies and understanding tumor biology.